Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Locatelli

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Molecular Cancer Therapeutics|April 29, 2010
Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical studyGiuseppe Locatelli, Roberta Bosotti, Marina Ciomei, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Science (New York, N.Y.)|January 26, 2019
Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammationMarta Joana Costa Jordão, Roman Sankowski, Stefanie M Brendecke, et al.
Molecular Cancer Therapeutics|August 5, 2010
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacyClara Albanese, Rachele Alzani, Nadia Amboldi, et al.
Glia|November 17, 2022
IGF1R expression by adult oligodendrocytes is not required in the steady-state but supports neuroinflammationGiuseppe Locatelli, Filipa Marques-Ferreira, Antonis Katsoulas, et al.
Nature Immunology|May 3, 2016
Origin, fate and dynamics of macrophages at central nervous system interfacesTobias Goldmann, Peter Wieghofer, Marta Joana Costa Jordão, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Nature Metabolism|July 10, 2023
Targeting the TCA cycle can ameliorate widespread axonal energy deficiency in neuroinflammatory lesionsYi-Heng Tai, Daniel Engels, Giuseppe Locatelli, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Molecular Cancer Therapeutics|April 29, 2010
Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical studyGiuseppe Locatelli, Roberta Bosotti, Marina Ciomei, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Science (New York, N.Y.)|January 26, 2019
Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammationMarta Joana Costa Jordão, Roman Sankowski, Stefanie M Brendecke, et al.
Molecular Cancer Therapeutics|August 5, 2010
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacyClara Albanese, Rachele Alzani, Nadia Amboldi, et al.
Glia|November 17, 2022
IGF1R expression by adult oligodendrocytes is not required in the steady-state but supports neuroinflammationGiuseppe Locatelli, Filipa Marques-Ferreira, Antonis Katsoulas, et al.
Nature Immunology|May 3, 2016
Origin, fate and dynamics of macrophages at central nervous system interfacesTobias Goldmann, Peter Wieghofer, Marta Joana Costa Jordão, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Nature Metabolism|July 10, 2023
Targeting the TCA cycle can ameliorate widespread axonal energy deficiency in neuroinflammatory lesionsYi-Heng Tai, Daniel Engels, Giuseppe Locatelli, et al.
Pageof 6